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splenic MZL samples expressed notch2 at a very high level, with a significant difference in comparison with B-SLL/CLL and MCL.
Microarray technology provides a powerful tool to assess the expression of a large number of genes in a single experiment. Several studies have demonstrated the ability of this technique to characterize gene expression profiles specific to a given cell population, with the aim to identify profiles relevant for diagnosis and prognosis 2, 3 or to identify novel tumor-specific markers for certain malignant diseases. 5 We used cDNA arrays to better characterize a heterogeneous group of lymphomas, non-follicular small B cell lymphomas. Our study confirms that gene expression profiling can identify parameters related to the heterogeneity of lymphoma and allows the differentiation of lymphoma subtypes. The diagnostic potential of a genomic-based analysis has already been reported in diffuse large B cell lymphomas (DLBL). 3, 6 Alizadeh et al 3 used lymphoid-specific cDNA arrays to identify two different subtypes of DLBL with different putative cells of origin (germinal center cells vs peripheral activated B cells) and demonstrated a correlation between cell of origin and outcome. In the second study, Shipp et al 6 analyzed the expression of an unselected set of 6817 genes related to cell adhesion, apoptosis, ras signaling, serine/threonine phosphorylation and tumor immunity using an Affymetrix microarray to predict different outcomes for DLBL patients. In CLL, two recently published studies focused on genomic 7 and proteomic profiles 8 and identified distinct sets of candidate genes. The numerous studies using these large-scale expression profiling technologies focusing on different issues are generating large amounts of data underscoring the power of this technique in medical research. However, these data are heterogeneous, both in terms of patient characteristics and in the way they are obtained using different array technologies. It therefore will be necessary to develop public resources, containing standardized different data sets obtained from different sources as proposed by the MGED group (http://www.mged.org).
In conclusion, we have demonstrated in this study that B-SLL/CLL, MZL and MCL possess specific transcriptional profiles that may be relevant to the pathogenesis of these histological subtypes. With a small set of genes, we are able to better identify this heterogeneous group of lymphoma. cation-generated mutations in the DNA binding runt domain have recently been reported in some cases of AML and MDS. [2] [3] [4] [5] [6] This new molecular lesion seems to be particularly frequent in M0-AML. Furthermore, Song et al 6 described the presence of AML1 mutations in a familial platelet disorder with a predisposition to develop AML (FDP/AML). In this work, we analyzed a consecutive series of myeloid malignancies and we found two new mutations which were localized outside of the runt domain of the AML1 gene.
C Thieblemont
A total of 30 patients with acute leukemia or MDS diagnosed following the FAB criteria were included in the study, as follows: M1 n = 4, M2 n = 5, M3 n = 1, M4 n = 3, M5 n = 9, CMML n = 1, RAEB and RAEBt n = 5 and hypoplastic AML n = 2 including one case of therapy-related AML. There were 20 males and 10 females with a median (range) age of 49.6 (10-84) years. DNA obtained from the bone marrow was purified by digestion with proteinase K, extraction by the 'salting out' method, and precipitation with ethanol. The configuration of the MLL locus was analyzed by hybridizing BamHI-and Hind III-digested DNA to the B859 probe. AML1-ETO and CBF␤-MYH11 transcripts were assayed by RT-PCR methods. The FLT-3 tandem duplication of the JM domain were studied using well established protocols.
7 D835 mutation was ruled out by means of DNA-PCR followed by EcoRV enzyme digestion.
Detection of AML1 gene mutations was studied by means of nonradiactive SSCP. The primers and PCR protocols devised to amplify exons 1 to 8 of the AML1 gene have been published elsewhere. 6 Direct sequencing was performed using forward and reverse primers in these cases with abnormal conformers on SSCP analysis using the ABI Prism dRhodamine Terminator Cycle Sequence Ready Reaction kit (PE Biosystems, Warrington, UK) and the ABI PRISM 310 Genetic Analyzer (Foster City, CA, USA).
Case 1 (Figure 1 ) was a 44 year-old man diagnosed as having a RAEB with a normal karyotype in July 1997. His past medical history was unremarkable. In June 1999 his medical status worsened, presenting persistent low levels of hemoglobin and platelets, and requiring frequent transfusions. He received chemotherapy with idarubicin, cytarabine and etoposide. Blasts counts in bone marrow decreased from 9% to 4-5%. In April 2000, the patient underwent an autologous bone marrow graft conditioned with cyclophosphamide and TBI at standard doses. Despite this, the blast count rose to 22%. In June 2000, the patient received an allogeneic BMT from a partially compatible sibling (two mismatches at HLA-A and the HLA-C loci, respectively). Granulocyte recovery ocurred on day 22. He suffered from an acute graft-versus-host disease (grade III) on day 35, which was unsuccessfully treated with corticosteroids. Simultaneously, blasts in peripheral blood reappeared showing a myeloid immunophenotype (CD34,CD33,CD117,CD123,HLA-DR) and a 6q deletion. In consequence, supportive measures were adopted and the patient died 40 days after the allogeneic transplant.
Case 2 ( Figure 2 ) was a 79 year-old man referred to the hospital due to anemia (hemoglobin: 109 g/l MCV: 96 fl), thrombocytopenia (83 × 10 9 /l) and leukocytosis with blastosis (11.47 × 10 9 /l WBC with 21% blasts). The patient was a smoker of 50 packs/year and was receiving thyroid hormone due to Hashimoto thyroiditis. An IgA monoclonal peak (19 g/l) was also recorded. A bone marrow aspirate revealed 44% of monocytic blast cells without noticeable dysplasia. The patient was therefore diagnosed as having acute monocytic leukemia. Treatment with 6-mercaptopurin at standard dose was started on a palliative basis. The patient died 2 weeks after the diagnosis of AML.
Both patients were negative for AML1-ETO and CBF␤-MYH11 rearrangements. MLL locus was in the germ line configuration. Neither FLT-3 tandem duplication nor D835 mutation was present in the above mentioned cases.
The first mutation (case 1, Figure 1 ) corresponded to a 55-bp deletion between the nucleotides 555 and 611. The normal allele was present on SSCP analysis. This microdeletion caused a frameshift and premature termination in exon 4. SSCP performed on DNA obtained from the donor sibling did not show abnormal results. Sequence analysis of the microdeletion region revealed a repeated motif GCCG(CT) at the end of the deleted sequence. This fitted perfectly the slipped mispairing model for the generation of deletions during the DNA replication. This motif/sequence is also present inside the runt domain of the AML1 gene, where most mutations have been reported to date. The pathogenic role of this mutation was supported by clinical findings. PCR performed during the follow-up (Figure 1 ) disclosed the disappearance of the band corresponding to the deleted sequence, just before the bone marrow transplantation. The abnormal band reappeared at the time of hematologic relapse.
The second mutation (case 2, Figure 2 ) corresponded to a missense mutation at alanin 60 (A60V). Sequencing analysis identified a C-to-T change in nucleotide 623 (GenBank accession number D4396). This change could also produce a new splice donor site (GT). SSCP showed an homozygous pattern indicating an allelic loss of the remaining AML1 allele. This case represents an additional example of AML1 biallelic disease. 4, 5 The AML1 gene encodes a 480 amino acid protein with an N-terminal transcriptional inhibitory domain (residues 1-76), the runt domain (residues 77-204), a C-terminal transcription inhibition domain (residues 204-317) and a C-terminal activation domain (residues 269-480). The region responsible for DNA binding and for heterodimerization is the runt domain. To date, most of the nontrans-
Figure 2
Top: Abnormal bands on SSCP analysis. Bottom left: 623 C→ T mutation is indicated (using the forward primer). Bottom right: 623 C→ T mutation is indicated (using the reverse primer).
locations generating mutations in the AML1 gene have been clustered within the runt domain. It should be noted that the mutations reported in this work were located outside the runt domain. The first mutation coded for a potentially abnormal AML1 protein altering the recognition function of the runt domain. In this sense, this case may be equivalent to previously reported mutations. [2] [3] [4] [5] [6] In contrast, the second case, affected a region where very few mutations have been found. 5 The low Senapathy score 8 calculated for this mutation suggests that this possible new donor splice site actually is silent. The functional meaning of this particular mutant warrants additional work. It should be pointed out that this mutation is not a polymorphism because it was not found in any other sample tested. These findings suggest that AML1 could harbor mutations in regions other than DNA binding runt domain.
5 AML-1 mutations may also be useful targets of minimal residual disease studies. 
TO THE EDITOR
The hematopoietic growth factor granulocyte colony-stimulating factor (G-CSF) regulates myeloid progenitor cell proliferation, differentiation and survival. G-CSF mediates its effects through interaction with the G-CSF receptor (G-CSFR) which leads to activation of intracellular signaling pathways, including the Janus tyrosine kinase/signal transducer and activator of transcription (JAK/STAT), ras/mitogen-activated protein kinase (MAPK), phosphatidylinositol (3)-kinase (PI3K)/AKT, and protein kinase C pathways (PKC). [1] [2] [3] The nuclear targets of most of these pathways have not been elucidated.
We previously demonstrated that the serum response element-1 (SRE-1) between nucleotides −418 and −391 of the egr-1 promoter is responsive to G-CSF in the myeloid leukemia cell line, NFS60. 4 The SRE-1 contains a central serum response element (SRE) and two adjacent ETS protein-binding sites (EBS). In electromobility shift assays, the serum response factor (SRF) binds constitutively to the CArG box of the SRE whereas the ETS protein Fli-1 binds the 5Ј Ets binding site (EBS). Furthermore, the SRE and EBSs of SRE-1 are each required for maximal transcriptional activation of a reporter construct containing a single copy of SRE-1 in response to G-CSF.
It has previously been shown that G-CSF stimulation of NFS60 cells activates RAS and the MAPK ERK1/2. 5 To determine if the MEK/ERK pathway is upstream of SRE-1 activation in response to G-CSF, NFS60 cells were transiently transfected with pTE2-SRE-1 or pTE2 and treated with the MEK 1 inhibitor, PD98059 prior to G-CSF stimulation. A dose-dependent decrease in pTE2-SRE-1 activity was observed at con-
Figure 1
G-CSF induces SRE-1 transcription through activation of MEK/ERK and PI3K/AKT pathways. (a, d and e) Serum-and growth factor-starved NFS60 cells (2 × 10 7
